Barriers and facilitators to implement the redispensing of unused oral anticancer drugs in clinical care: A hybrid-effectiveness type I study

Autor: Elisabeth M. Smale, Eva W. Verkerk, Eibert R. Heerdink, Toine C.G. Egberts, Bart J.F. van den Bemt, Charlotte L. Bekker

Publikováno v: Exploratory Research in Clinical and Social Pharmacy, Vol 15, Iss , Pp 100493- (2024)

Background: Minimizing medication waste through the redispensing of oral anticancer drugs (OADs) that were unused by patients provides economic and environmental benefits, but this is not yet universally implemented in clinical care. Objective(S): To

Externí odkaz: https://doaj.org/article/08df3f25dc9843aaaceebe8ab34c2a8b

Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements

Autor: Michelle W.J. Heijman, Aernoud T.L. Fiolet, Arend Mosterd, Jan G.P. Tijssen, Bart J.F. van den Bemt, Astrid Schut, John W. Eikelboom, Peter L. Thompson, Cornelia H.M. van den Ende, Stefan M. Nidorf, Calin D. Popa, Jan H. Cornel

Publikováno v: Annals of Internal Medicine C.2, 176, 6, pp. 737-742

Item does not contain fulltext BACKGROUND: Osteoarthritis is a major contributor to pain and disability worldwide. Given that inflammation plays an important role in the development of osteoarthritis, anti-inflammatory drugs may slow disease progress

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8983797e72ee6f5a774f28e282ae2907
https://doi.org/10.7326/m23-0289

Feasibility of an Individualized Dispensing Program for Patients Prescribed Oral Anticancer Drugs to Prevent Waste

Autor: Elisabeth M. Smale, Bas van Vlijmen, Hadewig B.B. Colen, Michel M. van den Heuvel, Ingrid M.E. Desar, Bart J.F. van den Bemt, Charlotte L. Bekker

Publikováno v: JCO Oncology Practice, 19, e618-e629
JCO Oncology Practice, 19, 4, pp. e618-e629

PURPOSE: Waste of oral anticancer drugs (OACDs) causes financial and environmental burdens. This study evaluates the feasibility of an individualized dispensing program to prevent waste of OACDs. METHODS: Adult patients were dispensed individualized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f6974c858ecd39464a9d0049cf9b2ec
https://doi.org/10.1200/OP.22.00553

Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study

Autor: Lieke H. Roest, Leanne J. Kosse, Jette A. van Lint, Helen R. Gosselt, Joep H.G. Scholl, Eugène van Puijenbroek, Harald E. Vonkeman, Sander W. Tas, Michael T. Nurmohamed, Bart J.F. van den Bemt, Naomi T. Jessurun

Publikováno v: Expert opinion on drug safety. Taylor and Francis Ltd.
Roest, L H, Kosse, L J, van Lint, J A, Gosselt, H R, Scholl, J H G, van Puijenbroek, E, Vonkeman, H E, Tas, S W, Nurmohamed, M T, van den Bemt, B J F & Jessurun, N T 2022, ' Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases : a registry-based prospective multicenter cohort study ', Expert opinion on drug safety . https://doi.org/10.1080/14740338.2022.2115479
Expert Opinion on Drug Safety, 22(3), 203-211. Taylor & Francis Ltd
Expert opinion on drug safety. Taylor & Francis
Expert Opinion on Drug Safety, 22, 203-211
Expert Opinion on Drug Safety, 22, 3, pp. 203-211

Contains fulltext : 291908.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which adverse drug reactions (ADRs) of biologics differ per immune-mediated inflammatory disease (IMID), and the relevance of tailoring ADR information pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84ea8bbb8a3dc59e6d557cb6544db47f
https://pure.amc.nl/en/publications/diseasespecific-adrs-of-tnf-inhibitors-as-reported-by-patients-with-inflammatory-rheumatic-diseases(3d23586c-85c0-4881-aedb-7c1d0844bbec).html